Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Accelerating Kids’ Access to Care Act of 2025
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R. 1509 - Accelerating Kids Access to Care Act Patient Access Act Issues related to patient access to treatment
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2026 · third_quarter · Q3
Rare Pediatric Disease Priority Review Voucher (PRV) Program Issues related to patient access to treatment
H.R. 9260 - LHHS Appropriations
Source: Senate LDA
H.R. 9260 - LHHS Appropriations
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R. 9260 - LHHS Appropriations
National Security Commission on emerging biotechnology policy proposals
Issues related to Section 232
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2026 · second_quarter · Q2
Issues related to supply chain Issues related to Section 232
H.R. 9260 - LHHS Appropriations
H.R. 1509 - Accelerating Kids Access to Care Act Patient Access Act Issues related to patient access to treatment
National Security Commission on emerging biotechnology policy proposals
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2026 · first_quarter · Q1
Duchenne Muscular Dystrophy and Rare Disease Patient Access to Treatments Newborn Screening for Rare Diseases
Scientific Innovation in Healthcare Gene Therapies Artificial Intelligence and Data Governance
Filing targets: HOUSE OF REPRESENTATIVES, SENATE